Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (2) 2007 addendum
Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (2) 2007 addendum
18 June 2007
National Institute for Health and Clinical Excellence
Summary,
National Institute for Health and Clinical Excellence
Summary,
Source: National Guidelines Clearinghouse
DISEASE/CONDITION(S)
- Alzheimer's disease (AD)
- Assessment of Therapeutic Effectiveness
- Management
- Treatment
- Family Practice
- Geriatrics
- Internal Medicine
- Neurology
- Pharmacology
- Psychiatry
- Advanced Practice Nurses
- Physician Assistants
- Physicians
- To provide an update review of the best quality evidence for the clinical effectiveness and cost-effectiveness of donepezil, rivastigmine, and galantamine for mild to moderately-severe Alzheimer's disease (AD)
- To provide a review of the best quality evidence for the clinical effectiveness and cost-effectiveness of memantine for moderately-severe to severe AD
